BRIEF published on 04/02/2026 at 04:05, 1 month 6 days ago Aperçu des résultats financiers de MedMira Inc. pour le deuxième trimestre de l'exercice 2026 Perte Nette Résultats Financiers De MedMira Frais D'exploitation Partenariat McKesson Chiffre D'affaires Du Deuxième Trimestre De L'exercice 2026
BRIEF published on 04/02/2026 at 04:05, 1 month 6 days ago MedMira Inc. Q2 FY2026 Financial Results Overview Net Loss Operating Expenses MedMira Financial Results McKesson Partnership Q2 FY2026 Revenue
PRESS RELEASE published on 04/02/2026 at 04:00, 1 month 6 days ago MedMira Reports Second Quarter Results FY2025 MedMira Inc. reports partnership with McKesson, financial results and progress on new tests. The company aims to expand market reach and improve sales Financial Results Clinical Trials MedMira Inc. RVF Technology McKesson Partnership
BRIEF published on 12/31/2025 at 02:05, 4 months 9 days ago MedMira Reports First Quarter Results for FY2026 Health Canada MedMira Q1 Financials MiROQ Technology Reveal® TP
BRIEF published on 12/31/2025 at 02:05, 4 months 9 days ago MedMira publie ses résultats du premier trimestre de l'exercice 2026 MedMira Santé Canada Technologie MiROQ Reveal® TP Résultats Financiers Du T1
PRESS RELEASE published on 12/31/2025 at 02:00, 4 months 9 days ago MedMira Reports First Quarter Results FY2026 MedMira Inc. reports Health Canada approval for Reveal® TP (Syphilis) rapid test, progress in clinical trials, and financial results for Q1 FY2026 Financial Results Clinical Trials MedMira Inc. Health Canada Approval Reveal® TP
BRIEF published on 11/29/2025 at 03:05, 5 months 9 days ago MedMira Releases FY2025 Financial Performance Financial Results MedMira Diagnostic Tests FY2025 MiROQ Technology
BRIEF published on 11/29/2025 at 03:05, 5 months 9 days ago MedMira publie ses résultats financiers pour l'exercice 2025 Résultats Financiers MedMira Exercice 2025 Tests Diagnostiques Technologie MiROQ
PRESS RELEASE published on 11/29/2025 at 03:00, 5 months 9 days ago MedMira Reports FY2025 Fourth Quarter and Year End Financial Results MedMira Inc. reports on financial results for FY2025, including product launches, clinical trials, and commercial advancements. Details on revenue, profit, loss, and balance sheet highlights are provided Financial Results Clinical Trials MedMira Inc. Product Launches Commercial Advancements
BRIEF published on 08/26/2025 at 22:48, 8 months 13 days ago Santé Canada approuve le test rapide de dépistage de la syphilis de MedMira Syphilis MedMira Santé Canada Tests Rapides Maladie Infectieuse
Published on 05/09/2026 at 01:30, 58 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 hours 28 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 5 hours 49 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 7 hours 15 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 7 hours 25 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 7 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 7 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 7 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 7 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 7 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
